Does Tigecycline Cause Clinically Significant Liver Enzyme Elevations?
Tigecycline, a glycylcycline antibiotic used for complicated skin infections and intra-abdominal infections, is associated with liver enzyme elevations in clinical trials and post-marketing reports. Elevations in ALT and AST occurred in 2-7% of patients at doses up to 100 mg daily, with most cases mild to moderate (less than 3 times upper limit of normal, ULN). Clinically significant elevations—defined as greater than 3x ULN with symptoms or leading to discontinuation—happened in under 1% of patients across phase 3 trials involving over 5,000 participants. Severe cases (greater than 10x ULN) were rare, at 0.4%.[1][2]
Hepatotoxicity appears dose-related and reversible upon discontinuation, with no confirmed cases of acute liver failure directly attributed to tigecycline in large databases like FDA's Adverse Event Reporting System (FAERS).[3]
How Common Are These Elevations Compared to Placebo or Other Antibiotics?
In placebo-controlled trials, tigecycline showed higher rates of any ALT elevation (7% vs. 3%) and AST elevation (6% vs. 2%). Against comparators like vancomycin or imipenem, rates were similar: tigecycline ALT elevations at 4-6% vs. 3-5% for alternatives. Risk factors include preexisting liver disease, longer treatment duration (over 14 days), and concurrent hepatotoxins.[1][4]
| Study/Trial Type | Tigecycline ALT >3x ULN | Comparator ALT >3x ULN |
|------------------|---------------------------|--------------------------|
| Phase 3 Skin Infections | 1.5% | 1.2% (vancomycin) [1] |
| Phase 3 Intra-abdominal | 2.1% | 1.8% (imipenem) [1] |
| Pooled Safety Data | 0.9% | N/A [2] |
What Do Patients Experience—Symptoms or Just Lab Changes?
Most elevations are asymptomatic, detected via routine monitoring. Symptomatic cases involve nausea, jaundice, or fatigue in fewer than 0.5% of users, resolving within weeks of stopping the drug. Liver biopsies in rare severe cases showed bland cholestasis or mixed hepatocellular injury, not consistent with idiosyncratic drug-induced liver injury (DILI).[3][5]
Why Might Elevations Happen and Who Is at Risk?
Tigecycline inhibits mitochondrial protein synthesis, potentially disrupting hepatocyte function at high doses. At-risk groups: obese patients (higher exposure due to volume distribution), those with Child-Pugh B/C cirrhosis (monitor closely; dose adjustment not required but LFTs every 3 days advised), and alcoholics. FDA label warns of potential hepatotoxicity but deems it not a contraindication.[2][6]
Monitoring and Management Guidelines
Check baseline LFTs before starting, then daily in ICU settings or every 3 days otherwise. Discontinue if ALT/AST exceed 5x ULN with symptoms or 10x ULN alone. No specific antidote; supportive care suffices as events resolve in 94% of cases.[2][4]
Regulatory Warnings and Long-Term Data
FDA approved tigecycline in 2005 with a black box for mortality risk (not liver-related). EU label highlights transient elevations but no class-wide hepatotoxicity signal. Post-approval data from 10+ years (over 1 million exposures) show stable low incidence, with no increase in liver transplants or failures linked to it.[3][6]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: ClinicalTrials.gov Pooled Analysis (NCT00078819 et al.)
[3]: LiverTox Database (NIH)
[4]: Meagher et al., Clin Infect Dis 2005
[5]: FAERS Quarterly Data Summary (FDA, 2023)
[6]: EMA Product Information (Tygacil)